Oncofertility: combination of ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval by Ralf Dittrich et al.
Dittrich et al. Reproductive Biology and Endocrinology 2013, 11:19
http://www.rbej.com/content/11/1/19RESEARCH Open AccessOncofertility: combination of ovarian stimulation
with subsequent ovarian tissue extraction on the
day of oocyte retrieval
Ralf Dittrich1*†, Laura Lotz1†, Andreas Mueller2, Inge Hoffmann1, David L Wachter3, Kerstin U Amann3,
Matthias W Beckmann1 and Thomas Hildebrandt1Abstract
Background: New anticancer treatments have increased survival rates for cancer patients, but often at the cost of
sterility. Several strategies are currently available for preserving fertility. However, the chances of achieving a
pregnancy with one technique are still limited. A combination of methods is therefore recommended in order to
maximize women’s chances of future fertility. In this retrospective study, ovarian stimulation with subsequent
ovarian tissue extraction on the day of oocyte retrieval were combined and the quality of the ovarian tissue, the
numbers and quality of oocytes, time requirements, and the safety of the strategy were examined.
Methods: Fourteen female patients suffering from malignant diseases underwent one in vitro fertilization cycle.
Different stimulation protocols were used, depending on the menstrual cycle. Transvaginal oocyte retrieval was
scheduled 34–36 h after human chorionic gonadotropin administration. Immediately afterwards, ovarian tissue was
extracted laparoscopically.
Results: A mean of 10 oocytes were retrieved per patient, and 67% of the oocytes were successfully fertilized using
intracytoplasmic sperm injection. No periprocedural complications and no complications leading to postponement
of the start of chemotherapy occurred. The ovarian tissues were of good quality, with a normal age-related follicular
distribution and without carcinoma cell invasion.
Conclusions: An approach using ovarian stimulation first, followed by laparoscopic collection of ovarian tissue, is a
useful strategy for increasing the efficacy of fertility preservation techniques. The ovarian tissue is not affected by
prior ovarian stimulation.
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In recent years, progress in the diagnosis and treatment
of oncological diseases has led to considerable improve-
ments in the survival prognosis, particularly in children
and adolescent cancer patients. Unfortunately, aggressive
chemotherapy and radiotherapy often cause infertility
due to massive destruction of the ovarian reserve,
resulting in premature ovarian failure. These women* Correspondence: ralf.dittrich@uk-erlangen.de
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reproduction in any medium, provided the orhave to face years of hormone replacement therapy and
the prospect of infertility, which causes psychological
stress [1,2].
Several strategies are currently available for preserving
fertility, depending on the risks and probability of go-
nadal failure, the patient’s general health at diagnosis,
and the partner’s status. These strategies include trans-
position of the ovaries before radiotherapy, ovarian
stimulation followed by cryopreservation of fertilized
oocytes or unfertilized oocytes, cryopreservation of
in vitro–matured oocytes, cryopreservation and trans-
plantation of ovarian tissue, and administration of
gonadotropin-releasing hormone (GnRH) agonists [3,4].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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available enables cancer patients to have children using
their own gametes after overcoming their disease, most
of these techniques are still experimental and the effi-
cacy of the individual techniques is limited. A combin-
ation of methods is therefore recommended in order to
maximize women’s chances of future fertility [5].
In this study, ovarian stimulation and ovarian tissue
cryopreservation were combined as a strategy for fertility
preservation in cancer patients. The aim was to evaluate
whether ovarian stimulation affects the quality of ovarian
tissue. The numbers and quality of oocytes, time require-
ments, and the safety of this strategy were also examined.
Methods
Fourteen patients between 24 and 35 years of age (me-
dian 29) were included in the retrospective study. They
were all suffering from malignant diseases (Table 1) and
wanted to preserve their fertility for a future pregnancy.
None of the patients had been treated with chemother-
apy or radiotherapy before the fertility preservation
procedure. All patients provided informed consent for
ovarian stimulation and ovarian tissue cryopreservation,
after receiving counseling on alternative options for fer-
tility preservation techniques. Three patients also wished
to be treated with GnRH agonists during chemotherapy.
Ovarian stimulation
All of the patients had regular menstrual cycles before
chemoradiotherapy. The phase of the menstrual cycleTable 1 Main characteristics and stimulation outcome in patie
stimulation and ovarian tissue cryopreservation
Patient Cancer type Age
1 Acute myelogenous leukemia 28
2 Hodgkin’s lymphoma 25
3 Cervix carcinoma 31
4 Leiomyosarcoma 26
5 Breast carcinoma 35
6 Breast carcinoma 31
7 Mesothelioma 26
8 Hodgkin’s lymphoma 24
9 Hodgkin’s lymphoma 30
10 Breast carcinoma 32
11 Breast carcinoma 30
12 Hodgkin’s lymphoma 25
13 Non-Hodgkin’s lymphoma 27
14 Breast carcinoma (hormone receptor–positive) 33
aStimulation started in the luteal phase.
bNo ICSI; oocytes were cryopreserved in an unfertilized state.
cReceived gonadotropin-releasing hormone agonists during cancer treatment.was evaluated using the onset of the last menstrual
period, ultrasonography, and progesterone concentra-
tions. Patients who were stimulated during the follicular
phase received either a short “flare-up” protocol or a
GnRH-antagonist protocol [6,7]. In the case of a single
patient, stimulation was started in the luteal phase with
a modified GnRH-antagonist protocol [8]. In one case,
ovarian stimulation was carried out with letrozole in
combination with a GnRH-antagonist protocol, due to
estrogen receptor–positive breast cancer [9,10].
Follicular growth was monitored using vaginal ultra-
sound and measurement of 17β-estradiol (E2) levels. The
gonadotropin dosage was adjusted according to the
preantral follicle count and follicle growth. A single dose
of recombinant human chorionic gonadotropin (hCG)
was administered when the lead follicle had a mean
diameter of 15–18 mm.
Oocyte and ovarian tissue collection
Transvaginal oocyte retrieval was scheduled 34–36 h
after hCG administration and was performed with the
patient under general anesthesia. Immediately after-
wards, ovarian tissue was extracted laparoscopically; the
stimulated ovary was divided along the longitudinal mid-
line with scissors, without the use of any diathermy.
During this procedure, an effort was made to avoid com-
ing too close to the ovarian mesentery, containing the
ovarian vessels. In this way, the anti-mesenteric half of
one ovary was separated and retrieved for cryopreserva-
tion, while the other half was left in situ. For hemostasisnts who provided informed consent for ovarian
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Figure 1 Histological analysis of ovarian tissue extracted
immediately after ovarian stimulation. Ovarian tissue with (A)
follicles and (B) one secondary follicle, stained with hematoxylin–
eosin (original magnification: × 20).
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was coagulated using bipolar diathermy. This was neces-
sary at points along the surface of the ovary and on the
ovarian septa between the former follicles.
The ovarian cortices were cryopreserved using a slow
freezing protocol and an open freezing system [11]. Prior
to freezing, a small biopsy of the ovarian tissue was ex-
amined histologically to assess follicle density and ex-
clude involvement of the tissue by malignancy.
The mature (metaphase II, MII) oocytes were fertilized
by intracytoplasmic sperm injection (ICSI) to avoid the
risk of fertilization failure with in vitro fertilization (IVF)
and cryopreserved at the pronuclear (PN) stage using a
slow freezing protocol in accordance with the patient’s
request and with German national law. If the patient did
not have a partner or the patient requested it, all oocytes
were cryopreserved in an unfertilized state using a slow
freezing protocol.
Results
All of the women underwent one IVF cycle. The median
period of the hormonal stimulation cycle, between the
start of hormonal stimulation and hCG administration,
was 10 days (range 6–13 days). The average number of
oocytes retrieved per patient was 10, and 67% of the oo-
cytes were successfully fertilized using ICSI. In three
cases, the oocytes were cryopreserved in an unfertilized
state (mean number of unfertilized oocytes 15) (Table 1).
The transvaginal oocyte retrieval and extraction of the
ovarian tissue immediately afterward were uneventful in
all cases. No perioperative complications such as severe
bleeding occurred. The fertility preservation procedures
did not lead to postponement of the start of chemother-
apy for any of the patients; however, one patient devel-
oped a mild ovarian hyperstimulation syndrome (OHSS).
The prefreezing histological sections from the human
ovarian grafts had a normal histological appearance. The
follicular count showed a normal age-related follicular
distribution, with the vast majority of follicles being
primordial. No carcinoma cells were seen in any of the
hematoxylin–eosin-stained slides examined (Figure 1).
Discussion
Ovarian stimulation, followed by intracytoplasmic sperm
injection and cryopreservation of embryos, is currently
the most successful procedure for fertility preservation
in newly diagnosed cancer patients. Depending on the
patient’s age, a survival rate of the embryos following
thawing of 35–90%, an implantation rate of up to 30%,
and a cumulative pregnancy rate of 30–40% can be
achieved [12,13].
Freezing unfertilized oocytes is also a promising option
for preserving fertility today. Oocyte banking does not
require any partner or sperm donor and it may alsoaccord better with various religious or ethical consider-
ations than embryo freezing. With recent improvements
in freeze–thaw protocols such as vitrification, promising
results with more than 60% of mature oocytes surviving
after thawing and subsequent fertilization have been
reported — rates comparable with fresh oocytes [14,15].
For either of these methods to be successful, however,
appropriate quantities of oocytes have to be obtained. In
addition, because the time frame up to the initiation of
chemotherapy and/or radiotherapy is limited, usually
only one IVF cycle can be carried out, and the numbers
of oocytes or embryos cryopreserved are consequently
often not sufficient for several transfer attempts. For
maximum effectiveness, combinations with other fertility
preservation techniques therefore need to be considered.
Cryopreservation of ovarian tissue offers an effective
combination. Cryopreservation of ovarian tissue before
oncologic treatment has recently become one of the most
promising techniques for preserving fertility. It allows
storage of a large number of primordial and primary folli-
cles. It can be carried out rapidly at any time in the men-
strual cycle without delaying the oncological treatment
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prepubertal or premenarchal female patients [16]. How-
ever, the method is surgically invasive and there is a po-
tential risk that malignant cells in the frozen tissue may
lead to recurrence of the primary disease after transplant-
ation. For most conditions, however, the risk is low and is
presumably related to the stage of disease at the time of
ovarian tissue cryopreservation, although considerable
caution is advisable with cryoconserved tissue from pa-
tients with leukemia, borderline ovarian tumor, or with a
high risk of ovarian metastases (e.g., in adenocarcinoma of
the cervix or stage III–IV breast cancer) [17]. A total of 20
live births have been reported to date after orthotopic
transplantation of cryopreserved ovarian tissue [18-21].
Although cryopreservation of ovarian tissue is still consid-
ered experimental, the technique is now gaining world-
wide acceptance.
In the cancer patients included in the present study,
ovarian stimulation was carried out first, followed by
laparoscopic collection of the ovarian tissue. Although it
has been reported that ovarian tissue is of poor quality
after ovarian stimulation [22], no data on this topic have
so far been published. Histological examination of the
ovarian tissue showed a normal age-related follicle distri-
bution. No histological differences were found from
ovarian tissue from patients who underwent ovarian tis-
sue cryopreservation in our department without prior
ovarian stimulation. Nor was any correlation noted be-
tween the numbers of oocytes retrieved and the follicle
distribution in the ovarian tissue. In patients with fewer
retrieved oocytes, the numbers of follicles were similar
to those in patients with a high response to ovarian
stimulation.
The ovarian response to stimulation is crucial for suc-
cessful fertility preservation, and there has been concern
regarding the ovarian response to ovarian stimulation in
cancer patients. In the present study, different stimula-
tion protocols were used due to the different starting
days for stimulation. Adequate numbers of oocytes were
retrieved within 2 weeks. The average number of oocytes
retrieved per patient was 10, and 67% of the oocytes
were successfully fertilized. This is in accordance with
recent studies that have reported no significant changes
in the ovarian reserve or response to gonadotropins in
patients with various types of cancer [19,20]. However,
other studies have reported a poorer ovarian response in
cancer patients undergoing IVF treatment protocols
[17,18]. The published data on this topic are still
inconsistent.
The present group of patients included five women with
breast cancer, one of whom had estrogen receptor–posi-
tive breast cancer. Concerns have been raised regarding
the use of controlled ovarian stimulation in patients with
hormone-dependent tumors, due to inadequate data onshort-term increases in hormonal effects on the tumor.
Moreover, as animal models suggest, estrogen may also
play a role in stimulating the growth of estrogen recep-
tor–negative breast cancers [23]. Conventional stimulation
protocols with gonadotropins are therefore modified to in-
clude administration of the aromatase inhibitor letrozole
[9,24] or the selective estrogen modulator tamoxifen [25].
These protocols have been used with success in reducing
the estradiol excesses that are normally seen with conven-
tional protocols, and short-term follow-up data for these
protocols have not shown any detrimental effects on
survival [10].
The risk of ovarian hyperstimulation syndrome
(OHSS) is a known complication of controlled ovarian
stimulation. One patient in the present study developed
a mild OHSS, but the start of cancer treatment did not
have to be postponed in any of the patients. The overall
risk of severe OHSS is low, and in cancer patients it is
also reduced, given that pregnancy will not occur; how-
ever, the risk should not be underestimated. Careful
selection of the gonadotropin starting dosage, close
monitoring, and step-down dosing are critical for
avoiding complications. Triggering using a GnRH agon-
ist alone or together with low-dose hCG might poten-
tially further reduce the risk of hyperstimulation [26,27].
A potential side effect of the subsequent use of oocyte
retrieval and ovarian tissue extraction may be bleeding
in the residual ovarian tissue. Stimulated ovaries are
more fragile than unstimulated ovarian tissue, which has
a more compact structure. Stimulated ovaries have to be
handled with greater care in comparison with unstimu-
lated ovaries, to avoid injuries to the surface and to
minimize possible tissue damage and bleeding. However,
no side effects of this type were observed in any of the
patients.
Several attempts have been made to improve the ef-
fectiveness of fertility preservation programs by combin-
ing different techniques. Removing ovarian tissue first
and starting ovarian stimulation approximately 1–2 days
later is an effective alternative approach. The partial re-
moval of ovarian tissue does not substantially affect the
average number or quality of oocytes retrieved after
ovarian stimulation [22].
The combination of cryopreservation of ovarian tissue
before chemotherapy and ovarian stimulation after the
start of chemotherapy should no longer be carried out,
as the efficacy of IVF is dramatically reduced even after
one round of chemotherapy and high rates of malforma-
tion of offspring after treatment with alkylating agents
have been demonstrated experimentally [28,29].
If there is no time for ovarian stimulation, cryopreser-
vation of oocytes retrieved during dissection of resected
ovarian tissue has also been reported as a potential strat-
egy for preserving fertility in patients with cancer. The
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cryopreservation prevents any delay in cancer treatment
and avoids the risks associated with high estradiol levels
in hormone-sensitive tumors [30]. Although healthy in-
fants have been born following IVM, implantation and
pregnancy rates are generally lower than for IVF with
mature oocytes [31,32].
Administration of GnRH-agonist analogs, in an attempt
to reduce the gonadotoxic effects of chemotherapy by
simulating a prepubertal hormonal milieu, is another fer-
tility preservation method and should be combined with
other fertility-protecting measures as well if possible. Al-
though conclusive proof is still awaited, there is increasing
evidence that GnRH agonists are effective in protecting
the ovaries [33]. Administration of these agents may be
considered on an individual basis, as the method is safe,
noninvasive, and easy to administer.
Conclusions
Fertility-preserving procedures should be offered to all
patients facing fertility loss before cytotoxic treatment is
administered. The decision as to which fertility preserva-
tion treatment is most suitable in the patient’s individual
situation has to be made during a personal discussion
with her and requires intensive interdisciplinary discus-
sion, including oncologists, radiotherapists, and repro-
ductive medicine specialists. A combination of fertility
preservation techniques increases the efficacy of the pro-
cedure and gives young cancer patients the best chance
for future fertility [5,34].
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